賽隆藥業(002898.SZ)：上半年業績盈轉虧至1321.3萬元
格隆匯 8 月 10日丨賽隆藥業(002898.SZ)披露2020年半年度報告，實現營業收入8843.55萬元，同比下降48.68%；歸屬於上市公司股東的淨虧損1321.3萬元，上年同期盈利2022.36萬元；歸屬於上市公司股東的扣除非經常性損益的淨虧損1301.83萬元，上年同期盈利2053.39萬元；基本每股虧損0.0826元。
2020年初，新冠疫情突如其來，各級醫療機構的診療服務及患者就醫計劃均受到影響，藥品終端需求明顯下降，同時物流配送、商業推廣、各省招投標準入工作均受到一定程度限制。疫情期間，公司在董事會的領導下，有序復工復產，繼續堅持以市場為導向，推進營銷改革，加大門冬氨酸鳥氨酸注射液、注射用胸腺法新、阿加曲班注射液、注射用替加環素等新產品的市場投入；加強內部管理，進一步提升企業的研發能力和成本控制能力，積極尋找新的利潤增長點，確保公司可持續發展。
在研發方面，研發充分利用藥品審評審批政策利好，積極推進藥品註冊並全面開展一致性評價工作。報告期內，取得了門冬氨酸鳥氨酸注射液《藥品註冊批件》及注射用多立培南《臨牀試驗通知書》；原料藥門冬氨酸鳥氨酸、埃索美拉唑鈉、多立培南已通過國家食品藥品監督管理總局藥品審評中心技術審評，審批結果為“A已批准在上市制劑使用的原料”。
報告期內獲批的門冬氨酸鳥氨酸注射液主要適用於因急、慢性肝病(如各型肝炎、肝硬化，脂肪肝、肝炎後綜合症)引發的血氨升高及治療肝性腦病，尤其適用於治療肝昏迷早期或肝昏迷期的意識模糊狀態，是繼近期注射用胸腺法新獲批後，公司在肝病用藥領域的又一次突破，且已經被列入2019年版《國家基本醫療保險、工傷保險和生育保險藥品目錄》。
在營銷方面，緊密結合當前醫改形勢及政策要求，以市場為導向不斷完善營銷體系，持續推進營銷改革，一是對各戰區各省區機構及人員配置進行調整，不斷完善銷售政策，調動一線人員的積極性；二是加大新產品的市場投入，強化縣級醫院和基層醫院的市場開發和覆蓋並拓展新渠道，加大民營醫院和院外銷售的力度；三是強化學術推廣，大力開展重點區域的招商及學術推廣工作；四是注重銷售人才梯隊建設，加強內部培訓和績效考核，提升銷售人員業務水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
